SMC recommends Eladynos for postmenopausal osteoporosis in Scotland
Ella Day | July 8, 2025 | News story | Medical Communications, Research and Development | Musculo-skeletal disorder, NHS, Scottish Medicine Consortium, Theramex, clinical trials, osteoporosis, postmenopause
Theramex, a women’s health pharma company, has announced that the Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for NHS use in Scotland. This offers a new treatment option for postmenopausal women at high risk of fracture.
Osteoporosis is a progressive condition causing fragile bones and fractures. Hip fractures alone are responsible for around 50% of fracture-related deaths in women. Many patients remain undiagnosed or untreated, and fractures often recur before osteoporosis is identified.
Eladynos is an anabolic therapy and works by stimulating new bone formation to strengthen bones and reduce the risk of fracture. Clinical trials, including the ACTIVE and ACTIVExtend studies, showed significant reductions in vertebral fractures and consistent protection when followed by bisphosphonate therapy. It is a once-daily injection and recommended for up to 18 months of treatment.
Tina Backhouse, UK general manager at Theramex, stated: “With women at a five times greater risk of osteoporosis than men, I am thrilled that we are able to expand access further across the UK and bring this treatment to women in Scotland.”
The approval follows previous guidance from NICE and means that, for the first time, women in Scotland will have NHS access to this treatment. However, charities warn that gaps in care remain, with many high-risk patients still missing out on timely diagnosis and treatment.
Ella Day
8/7/25
Related Content
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
From sickness to prevention: the case for population health management
In the third of the Gateway to Local Adoption series, Visions4Health caught up with James …
From Vaccine Innovation Pathway to growth powerhouse: how the UK is transforming clinical trials
Commercial clinical trials are a high-value growth driver for a country’s health and the economy …
